Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine
Issued Date
2022-04-01
Resource Type
ISSN
15423565
eISSN
15427714
Scopus ID
2-s2.0-85110522121
Pubmed ID
34089852
Journal Title
Clinical Gastroenterology and Hepatology
Volume
20
Issue
4
Start Page
874
End Page
885.e4
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Gastroenterology and Hepatology Vol.20 No.4 (2022) , 874-885.e4
Suggested Citation
Park J. Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. Clinical Gastroenterology and Hepatology Vol.20 No.4 (2022) , 874-885.e4. 885.e4. doi:10.1016/j.cgh.2021.05.062 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/87350
Title
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine
Author(s)
Author's Affiliation
Siriraj Hospital
Osaka Metropolitan University Graduate School of Medicine
Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Massey University Wellington
Good Gang-An Hospital
Academia Sinica, Genomics Research Center
E-Da Hospital
Shanghai Jiao Tong University School of Medicine
Chang Gung University College of Medicine
Kaohsiung Medical University Chung-Ho Memorial Hospital
National Taiwan University Hospital
Saga University Hospital
China Medical University Hospital
Eulji University, School of Medicine
Palo Alto Medical Foundation
Hanyang University College of Medicine
Kyung Hee Medical Center
Soonchunhyang University, College of Medicine
Chulabhorn Royal Academy
Kyushu University Hospital
Kumamoto University
Stanford Healthcare
Stanford University
Auckland City Hospital
College of Medicine
Sungkyunkwan University
The University of Hong Kong
Hallym University, College of Medicine
Medical School of Nanjing University
Chinese University of Hong Kong
Ogaki Municipal Hospital
Santa Clara Valley Medical Center
Seoul National University College of Medicine
Wong Clinics
San Jose Gastroenterology
Chinese Hospital
National Medical Center
Osaka Metropolitan University Graduate School of Medicine
Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Massey University Wellington
Good Gang-An Hospital
Academia Sinica, Genomics Research Center
E-Da Hospital
Shanghai Jiao Tong University School of Medicine
Chang Gung University College of Medicine
Kaohsiung Medical University Chung-Ho Memorial Hospital
National Taiwan University Hospital
Saga University Hospital
China Medical University Hospital
Eulji University, School of Medicine
Palo Alto Medical Foundation
Hanyang University College of Medicine
Kyung Hee Medical Center
Soonchunhyang University, College of Medicine
Chulabhorn Royal Academy
Kyushu University Hospital
Kumamoto University
Stanford Healthcare
Stanford University
Auckland City Hospital
College of Medicine
Sungkyunkwan University
The University of Hong Kong
Hallym University, College of Medicine
Medical School of Nanjing University
Chinese University of Hong Kong
Ogaki Municipal Hospital
Santa Clara Valley Medical Center
Seoul National University College of Medicine
Wong Clinics
San Jose Gastroenterology
Chinese Hospital
National Medical Center
Other Contributor(s)
Abstract
Background & AIMS: Antiviral treatment criteria are based on disease progression risk, and hepatocellular carcinoma (HCC) surveillance recommendations for patients with chronic hepatitis B (CHB) without cirrhosis is based on an annual incidence threshold of 0.2%. However, accurate and precise disease progression estimate data are limited. Thus, we aimed to determine rates of cirrhosis and HCC development stratified by age, sex, treatment status, and disease activity based on the 2018 American Association for the Study of Liver Diseases and 2017 European Association for the Study of the Liver guidelines. Methods: We analyzed 18,338 patients (8914 treated, 9424 untreated) from 6 centers from the United States and 27 centers from Asia-Pacific countries. The Kaplan-Meier method was used to estimate annual progression rates to cirrhosis or HCC in person-years. Results: The cohort was 63% male, with a mean age of 46.19 years, with baseline cirrhosis of 14.3% and median follow up of 9.60 years. By American Association for the Study of Liver Diseases criteria, depending on age, sex, and disease activity, annual incidence rates ranged from 0.07% to 3.94% for cirrhosis, from 0.04% to 2.19% for HCC in patients without cirrhosis, and from 0.40% to 8.83% for HCC in patients with cirrhosis. Several subgroups of patients without cirrhosis including males younger than 40 years of age and females younger than 50 years of age had annual HCC risk near or exceeding 0.2%. Similar results were found using European Association for the Study of the Liver criteria. Conclusion: There is great variability in CHB disease progression rates even among “lower-risk” populations. Future CHB modeling studies, public health planning, and HCC surveillance recommendation should be based on more precise disease progression rates based on sex, age, and disease activity, plus treatment status.